SCLX News - Candlesense

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali’s Shareholders of the Previously Announced Business Combination

(NASDAQ:SCLX) PALO ALTO, Calif, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a majority-owned subsidiary of Scilex Holding Company (“Scilex” or the “Company”) (Nasd...

What are the key regulatory and product development milestones that could drive the stock’s performance after the merger? How will the SPAC transaction affect shareholder dilution and the overall capital structure? What are the expected financial synergies and impact on earnings per share post‑combination?

Mergers

6 days ago

Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16

PALO ALTO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing a...

How does this financing round compare to recent capital raises by peers in the non‑opioid pain‑management space, and what does it indicate about market confidence in Semnur’s pipeline? What is the projected timeline and probability of success for the Phase 3 trial of SP‑102, and how could trial outcomes impact valuation? How will the $20 million private placement at $16 per share affect dilution and the current share price of SCLX?

Financing

20 days ago

Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex

PALO ALTO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX) , an innovative revenue-generating company focused on acquiring, developing ...

What is the anticipated impact on liquidity and trading volume for both Scilex and Denali’s securities after the merger? How might the market’s perception of non‑opioid pain management assets influence the long‑term outlook for the combined entity? Will there be any changes to the management team or board composition after the merger, and how might that influence investor confidence?

Mergers

28 days ago